Updated 2026-09 · 6 min read
Burn-R is a triple-agonist metabolic peptide — 39 residues engaging three receptors in a single molecule: the GIP, GLP-1, and glucagon receptors. This guide reviews the mechanism of triple-receptor agonism reported in preclinical work and in the TRIUMPH trial literature. It is a research-use compound; nothing here concerns use in humans or animals.
The three receptors
GLP-1 and GIP are incretin receptors, central to insulin signaling and energy-balance pathways in research models. The glucagon receptor adds an energy-expenditure axis the incretin agonists alone do not engage. Concurrent agonism at all three is the mechanistic premise: the endpoints studied for the triple agonist differ from those of the dual and single agonists precisely because of the glucagon arm.
Literature context
The triple agonist has been evaluated for metabolic and body-composition endpoints in the TRIUMPH trial program and in preclinical models. This guide summarizes that literature as mechanism context; it makes no claim of safety, efficacy, or suitability for any use.
Where it sits in the line
Burn-R is the triple agonist; Burn-T is the dual GIP/GLP-1 agonist; Burn-S is the GLP-1 agonist. The line spans the incretin mechanisms studied in metabolic research, from single- to triple-receptor engagement.
In the catalog
This material is synthesized from publicly available preclinical literature and industry documentation for qualified laboratory researchers. It is not medical, veterinary, therapeutic, or diagnostic advice. All compounds are supplied and discussed solely for in-vitro laboratory research and are not for human or animal use.